Statistics from Altmetric.com
In the article on page 19 of the February issue (D W Gilley. Cholinesterase inhibitors reduce burden and care time for informal carers of people with Alzheimer’s disease. Evid Based Ment Health 2006;9:19) there was an error in the notes section. The meta-analysis did not include NMDA receptor agonists, although the narrative review did. The unapproved drugs velnacrine and metrifonate are classified as acetylcholinesterase inhibitors (ChEIs), not NMDA receptor agonists. As ChEIs, these drugs were included in the meta-analysis. Please refer to the original article (Linger JH, Martire LM, Schulz R. Caregiver specific outcomes in antidementia clinical drug trials: a systematic review and meta-analysis. J Am Geriatr Soc 2005;53:983–90.) for appropriate phrasing as to the limitation posed by the inclusion of these agents.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.